Skip to main content
BEAT
NASDAQ Industrial Applications And Services

HeartBeam CEO Departs, Director Resigns Amid Strategic Pivot to Licensing Model

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.698
Mkt Cap
$38.477M
52W Low
$0.54
52W High
$4
52W Position info
29% above low
Off High info
83% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

BEAT sits 29% above its 52-week low of $0.54.

Summary

HeartBeam announced a major strategic reorganization, including the departure of its CEO and a director, as it shifts its business model to licensing its 3D ECG technology for global adoption and a leaner cost structure.


Key Events · Executive and Board Changes · BEAT

  • CEO Robert Eno Departs

    Robert P. Eno mutually agreed to depart as Chief Executive Officer, Board member, and principal executive officer, effective June 30, 2026, as part of a strategic reorganization. He is expected to transition to a consulting role.

  • Interim Leadership Appointed

    Branislav Vajdic, Ph.D., Founder and President, will serve as the principal executive officer, and Rich Ferrari, Executive Chairman, will lead focused implementation teams during the transition.

  • Director Mark Strome Resigns

    Mark Strome resigned from the Board of Directors and all committees, effective immediately. This follows his significant stock purchase in the company's April public offering.

  • Major Strategic Business Model Shift

    The company is pivoting from direct medical device sales to licensing its 3D ECG signal technology to established partners, aiming for global market reach and a 'meaningfully lower cost structure'.


Analysis · BEAT · Industrial Applications And Services

This 8-K announces a significant strategic reorganization for HeartBeam, including the departure of CEO Robert Eno and Director Mark Strome. The company is pivoting its business model from direct sales to a licensing strategy for its 3D ECG signal technology, aiming for global adoption and a 'meaningfully lower cost structure.' This major shift, coupled with leadership changes, is critical for a micro-cap company that recently raised capital and continues to face a 'going concern' warning, as it seeks a more capital-efficient path to commercialization and expansion into new areas like heart attack detection.

At the time of this filing, BEAT was trading at $0.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $38.5M. The 52-week trading range was $0.54 to $4.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BEAT - Latest Insights

BEAT
Aug 05, 2026, 6:16 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $0.4998
Real-time Price: $0.514 info
Change: +$0.0142 (+3%) info
Market Cap: $28.331M info
BEAT
Aug 03, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4899
Real-time Price: $0.514 info
Change: +$0.0241 (+5%) info
Market Cap: $28.331M info
BEAT
Jul 02, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.720
Real-time Price: $0.514 info
Change: -$0.206 (-29%) info
Market Cap: $28.331M info
BEAT
Jun 24, 2026, 4:09 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.692601
Real-time Price: $0.514 info
Change: -$0.178601 (-26%) info
Market Cap: $28.331M info
BEAT
Jun 22, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7199
Real-time Price: $0.514 info
Change: -$0.2059 (-29%) info
Market Cap: $28.331M info